OVOS Natural Health Inc. launches VIVIMIND(tm) in Canada

CALGARY, Nov. 28, 2011 /CNW Telbec/ - OVOS Natural Health Inc. ("OVOS"), a wholly-owned subsidiary of Advanced Orthomolecular Research Inc. ("AOR") and AOR's exclusive Canadian partner, BELLUS Health Inc. (TSX: BLU) ("BELLUS Health"), announced today the official launch of VIVIMIND™ in Canada.  VIVIMIND™ is being made available to Canadian consumers initially at www.vivimind.ca and will be gradually introduced alongside OVOS' portfolio of natural health products at specific points of sale throughout Canada.

"Providing health practitioners and consumers with science-backed natural health products is what guides AOR, and we are very pleased to be launching VIVIMIND™ today, our first science-backed product to be launched through our wholly-owned subsidiary, OVOS. We are excited about the prospect of making this unique Health Canada-approved product in the cognition field accessible to all Canadians" said Mr. Clark Sayer, Managing Director at AOR.

"The launch of VIVIMIND™ in Canada represents an important milestone for BELLUS Health", said Roberto Bellini, President and Chief Executive Officer of BELLUS Health. "In partnership with AOR and OVOS, leaders in the nutraceutical field in Canada, we look forward to providing an innovative solution to the rapidly growing need in the cognitive health area" concluded Mr. Bellini.

About VIVIMIND™
VIVIMIND™ is scientifically proven to help support the specific area of the brain known as the hippocampus, a region responsible for memory and learning. The active ingredient behind VIVIMIND™, homotaurine, is a naturally occurring amino acid with unique properties found in certain seaweeds. VIVIMIND™ is intended to be used in normal aging adults.

VIVIMIND™ was subject to more than 15 years of significant scientific research, including clinical testing in over 2,000 people at European, American and Canadian medical centres. In a large, controlled clinical study, VIVIMIND™ was shown to reduce by 68% the hippocampus volume loss in Alzheimer's disease patients over 18 months.¹

Regulatory approvals for the commercial sale of VIVIMIND™ were obtained in Italy and in Spain in 2009, and a Natural Health Product Number was issued by Health Canada for VIVIMIND™ in September 2010.  For more information on VIVIMIND™, please visit www.vivimind.ca.

About OVOS Natural Health
OVOS was founded in 2008 as manufacturer of natural health supplement products. The first product launched by OVOS is VIVIMIND™, and will soon be accompanied by other natural products based on sound scientific research.

About Advanced Orthomolecular Research
AOR has an established reputation as the most advanced supplement formulator in Canada. AOR consistently puts science-backed vitamin supplements and natural health products into the hands of health practitioners and into the lives of patients, insisting on solid science and real-world outcomes. AOR's portfolio of products includes over 160 vitamin supplements and natural health products.  For further information on AOR, please visit www.AOR.ca.

About BELLUS Health
BELLUS Health is a development-focused health company concentrating on the development of products that provide innovative health solutions and address critical unmet medical needs. For further information on BELLUS Health, please visit www.bellushealth.com.

Forward Looking Statements
Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements.  Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control.  Such risks include but are not limited to: the ability to obtain financing immediately in current markets, the impact of general economic conditions, general conditions in the pharmaceutical and/or nutraceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Group does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation, achievement of forecasted burn rate, and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed.  Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.  The reader should not place undue reliance, if any, on any forward-looking statements included in this news release.  These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.  Please see the Company's public fillings including the Annual Information Form of BELLUS Health Inc. for further risk factors that might affect the BELLUS Health Group and its business

1 Gauthier S. et al, Journal Nutrition Health Aging, 2009; 13 (6): 550-7